Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0039483 (
giant cell arteritis
)
3,204
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PTX3
is a prototypic soluble pattern recognition receptor, expressed at sites of inflammation and involved in regulation of the tissue homeostasis.
PTX3
systemic levels increase in many (but not all) immune-mediated inflammatory conditions. Research on
PTX3
as a biomarker has so far focused on single diseases. Here, we performed a multi-group comparative study with the aim of identifying clinical and pathophysiological phenotypes associated with
PTX3
release.
PTX3
concentration was measured by ELISA in the plasma of 366 subjects, including 96 patients with
giant cell arteritis
(
GCA
), 42 with Takayasu's arteritis (TA), 10 with polymyalgia rheumatica (PMR), 63 with ANCA-associated systemic small vessel vasculitides (AAV), 55 with systemic lupus erythematosus (SLE), 21 with rheumatoid arthritis (RA) and 79 healthy controls (HC). Patients with SLE, AAV, TA and
GCA
, but not patients with RA and PMR, had higher
PTX3
levels than HC.
PTX3
concentration correlated with disease activity, acute phase reactants and prednisone dose. It was higher in females, in patients with recent-onset disease and in those with previous or current active vasculitis at univariate analysis. Active small- or large- vessel vasculitis were the main independent variables influencing
PTX3
levels at multivariate analysis. High levels of
PTX3
in the blood can contribute to identify an increased risk of vascular involvement in patients with systemic immune-mediated diseases.
...
PMID:PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. 3139 40